• Contact Us
  • Sign Up
  • TWITTER
Microbiome Times Magazine

Drug Database Powered by:

  • Human Health
  • Finance
  • Drug Database
    • Login/ Register
    • About
  • Issue Archive
  • Advertise
  • Microbiome Job Board

Month: March 2022

Pharma & Human Health

Researchers identify potential approaches to modify the vaginal microbiome

March 30, 2022 Microbiome Times

The female genital tract is naturally colonized by mixed communities of bacteria, known as the vaginal microbiome. When these communities are dominated by species such as Lactobacillus crispatus, they provide important protective functions in genital health. […]

Finance

How insights from the field of advanced therapy medicinal products (ATMPs) can inform solutions in the microbiome field

March 23, 2022 Microbiome Times

Upcoming panel at Pharmabiotics Conference & Partnering 2022 will explore what microbiome drug developers can learn from another area of pharmaceutical innovation Live Biotherapeutic Products (LBPs) emerging from microbiome-related scientific innovation are novel and exciting […]

Pharma & Human Health

A new photoactive viral vector for anti-cancer therapy has been developed

March 15, 2022 Microbiome Times

A research team at the University of Bologna has developed a new targeted cancer therapy based on the action of a genetically modified phage, a virus that infects bacteria. The study made the cover of […]

Finance

Pherecydes Pharma and BIOASTER Join Forces in the Treatment of Bacteremia

March 14, 2022 Microbiome Times

Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, and BIOASTER, the first Institute for Technological Innovation in Microbiology, announce the implementation of research collaboration to use […]

Pharma & Human Health

Deciphering gut microbiome ‘chatter’ to combat IBD

March 14, 2022 Microbiome Times

Scientists at the Earlham Institute, Quadram Institute and University of East Anglia on the Norwich Research Park, have developed a new computational biology method to better understand IBD for targeted clinical treatments. By analysing specific […]

Finance

SNIPR BIOME announces opening of new BSL2/GMO2-classified laboratory in Copenhagen, Denmark

March 9, 2022 Microbiome Times

SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, is opening a 175 square meter state-of-the-art BSL2/GMO2-classified laboratory in Copenhagen. The new facilities will be among the largest GMO2 laboratories in Scandinavia and Northern […]

Finance

Microbiotica raises $67M to advance pipeline of microbiome-based therapeutics

March 9, 2022 Microbiome Times

Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and biomarkers, today announced the completion of a £50 million ($67 million) Series B financing round – the largest microbiome-related financing in Europe to date. […]

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • Validation of the predictive role of A.muciniphila for response and resistance to PD1 blockade in non small cell lung cancers
    April 15, 2022
  • Did you miss Probiota Copenhagen 2022? Catch up now!
    April 12, 2022
  • A new strategy for editing DNA within microbial communities using CRISPR-Cas9 technology
    February 18, 2022
  • Protecting and Preserving the Intestinal Microbiome from Antibiotic-induced Dysbiosis with DAV132
    February 17, 2022
  • ELIGO v SNIPR: a reflection on IP strategies in a competitive environment
    February 7, 2022
sign up

Sign up to the Microbiome Times newsletter